Currently out of the existing stock ratings of Sumant Kulkarni, 109 are a BUY (86.51%), 17 are a HOLD (13.49%).

Sumant Kulkarni

Work Performance Price Targets & Ratings Chart

Analyst Sumant Kulkarni works at CANACCORD with a stock forecast success ratio of 32.36% fulfilled within 140.44 days on average.

Sumant Kulkarni’s has documented 255 price targets and ratings displayed on 18 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on ITCI, Intracellular Th at 23-Feb-2024.

Wall Street Analyst Sumant Kulkarni

Analyst best performing recommendations are on CRTX (CORTEXYME).
The best stock recommendation documented was for CRTX (CORTEXYME) at 6/3/2019. The price target of $42 was fulfilled within 15 days with a profit of $17.87 (74.06%) receiving and performance score of 49.37.

Average potential price target upside

ACAD ACADIA Pharmaceuticals ATAI ATAI Life Sciences BV BHVN Biohaven Pharmaceutical Holding Co Ltd BIIB Biogen BTAI BioXcel Therapeutics CRTX Cortexyme ITCI Intracellular Th NBIX Neurocrine Biosciences SAGE Sage Therapeutic VYGR Voyager Therapeutics ZYNE Zynerba Pharmaceuticals CARA Cara Therapeutic CMPS Compass Pathways Plc CYBN Cybin  KMPH KemPharm TEVA Teva Pharma Industries Ltd ADR ALDR Alder BioPharmaceuticals CLNN Clene .

Analyst name

Rating

Current price target

Potential distance

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

42

$15.64 (59.33%)

42

2 days ago

25/33 (75.76%)

$15.64 (59.33%)

486

Buy

39

$12.64 (47.95%)

40

2 days ago

5/10 (50%)

$12.64 (47.95%)

58

Buy

33

$6.64 (25.19%)

33

2 days ago

8/19 (42.11%)

$6.64 (25.19%)

119

Buy

36

$9.64 (36.57%)

2 days ago

0/1 (0%)

$9.64 (36.57%)

Buy

35

$8.64 (32.78%)

33

2 days ago

10/16 (62.5%)

$8.64 (32.78%)

235

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Sumant Kulkarni is most bullish on?

Potential upside of $87.99 has been obtained for BIIB (BIOGEN)

Which stock is Sumant Kulkarni is most reserved on?

Potential downside of $19.6 has been obtained for NBIX (NEUROCRINE BIOSCIENCES)

What Year was the first public recommendation made by Sumant Kulkarni?

On 2012

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?